ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 746 USD | -0.64% |
|
-1.80% | +27.97% |
Financials (USD)
| Sales 2024 * | 41.36B | Sales 2025 * | 51.35B | Capitalization | 676B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.92B | Net income 2025 * | 15.82B | EV / Sales 2024 * | 16.7 x |
| Net Debt 2024 * | 15.19B | Net Debt 2025 * | 10.74B | EV / Sales 2025 * | 13.4 x |
| P/E ratio 2024 * |
61.8
x | P/E ratio 2025 * |
41.8
x | Employees | 43,000 |
| Yield 2024 * |
0.69% | Yield 2025 * |
0.8% | Free-Float | 99.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.64% | ||
| 1 week | -1.80% | ||
| Current month | -4.11% | ||
| 1 month | -2.19% | ||
| 3 months | +19.67% | ||
| 6 months | +22.84% | ||
| Current year | +27.97% |
1 week
743.00
771.83
1 month
743.00793.67
Current year
579.05800.78
1 year
369.76800.78
3 years
178.58800.78
5 years
101.36800.78
10 years
57.35800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +2.91% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 746 | -0.64% | 1,717,347 |
| 24-04-17 | 750.8 | +0.54% | 3,069,367 |
| 24-04-16 | 746.7 | -0.54% | 2,569,799 |
| 24-04-15 | 750.8 | -0.12% | 2,358,569 |
| 24-04-12 | 751.6 | -1.05% | 2,495,037 |
Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
750.8
USD
Average target price
813.3
USD
Spread / Average Target
+8.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B | |
| -8.80% | 142B |
- Stock Market
- Equities
- LLY Stock
